Case Studies
Real Cases. Real World. Real Impact.
Our case studies feature real-world examples of our expertise in action, across
HEOR and market access, patient-centered outcomes, and analytics projects. Find
out more below.
Analysis of real-world data for HTA submission
Vitaccess is partnering with a pharmaceutical company on an international, patient-centric real-world evidence (RWE) study. This observational longitudinal study is designed to increase understanding of the impact of living with a rare autoimmune, neuromuscular disease.
Transfusion-dependent ß-thalassemia (TDT)
Real-world rare disease insights from daily patient reports used to support biotech reimbursement submissionJun 25, 2025 8 min Case Studies Download Full Case Study Copy Link In collaboration with patient advocates and scientific advisors, Vitaccess has supported a...
Cystic Fibrosis Case Study
Flexible patient-centric study demonstrating real-world impact of therapy in late-stage developmentJun 25, 2025 8 min Case Studies Download Full Case Study Copy Link Vitaccess has assisted a US-based biopharmaceutical company in generating evidence on CF treatment...
Melanoma Case Study
Innovative Vitaccess Real™ platform has been harnessed in a long-term real-world observational study in melanoma, developed in collaboration with a UK-based charity and melanoma patients.
Charcot-Marie-Tooth Disease
Innovative patient-centric digital observational study in rare disease. Innovative research organization, Vitaccess, has leveraged its flexible platform to connect a European biopharmaceutical company in real time to Charcot-Marie-Tooth disease (CMT) patients worldwide.
Myasthenia Gravis
Vitaccess has collaborated with clinicians and patient representatives to connect a European biotechnology company with a global cohort of myasthenia gravis (MG) patients. Our client is using the data in pharmacoeconomic models and reimbursement submissions.
Innovative caregiver burden study for HTA
Vitaccess is partnering with a pharmaceutical company on an international, patient-centric real-world evidence (RWE) study. This observational longitudinal study is designed to identify and increase understanding of the impact of living with a rare autoimmune, neuromuscular disease.
The client is seeking recommendation from health technology assessment (HTA) bodies across Europe for a new product to treat this disease. Some HTA bodies will include impact on caregiver burden within the value assessment of new health technologies, however, there is a gap in research on the health-related quality of life of the caregivers of patients living with the disease.
Analysis of real-world data for HTA submission
Vitaccess is partnering with a pharmaceutical company on an international, patient-centric real-world evidence (RWE) study. This observational longitudinal study is designed to increase understanding of the impact of living with a rare autoimmune, neuromuscular disease.
Transfusion-dependent ß-thalassemia (TDT)
Real-world rare disease insights from daily patient reports used to support biotech reimbursement submissionJun 25, 2025 8 min Case Studies Download Full Case Study Copy Link In collaboration with patient advocates and scientific advisors, Vitaccess has supported a...
Cystic Fibrosis Case Study
Flexible patient-centric study demonstrating real-world impact of therapy in late-stage developmentJun 25, 2025 8 min Case Studies Download Full Case Study Copy Link Vitaccess has assisted a US-based biopharmaceutical company in generating evidence on CF treatment...
Melanoma Case Study
Innovative Vitaccess Real™ platform has been harnessed in a long-term real-world observational study in melanoma, developed in collaboration with a UK-based charity and melanoma patients.
Charcot-Marie-Tooth Disease
Innovative patient-centric digital observational study in rare disease. Innovative research organization, Vitaccess, has leveraged its flexible platform to connect a European biopharmaceutical company in real time to Charcot-Marie-Tooth disease (CMT) patients worldwide.
Myasthenia Gravis
Vitaccess has collaborated with clinicians and patient representatives to connect a European biotechnology company with a global cohort of myasthenia gravis (MG) patients. Our client is using the data in pharmacoeconomic models and reimbursement submissions.
Innovative caregiver burden study for HTA
Vitaccess is partnering with a pharmaceutical company on an international, patient-centric real-world evidence (RWE) study. This observational longitudinal study is designed to identify and increase understanding of the impact of living with a rare autoimmune, neuromuscular disease.
The client is seeking recommendation from health technology assessment (HTA) bodies across Europe for a new product to treat this disease. Some HTA bodies will include impact on caregiver burden within the value assessment of new health technologies, however, there is a gap in research on the health-related quality of life of the caregivers of patients living with the disease.
Analysis of real-world data for HTA submission
Vitaccess is partnering with a pharmaceutical company on an international, patient-centric real-world evidence (RWE) study. This observational longitudinal study is designed to increase understanding of the impact of living with a rare autoimmune, neuromuscular disease.
Transfusion-dependent ß-thalassemia (TDT)
Real-world rare disease insights from daily patient reports used to support biotech reimbursement submissionJun 25, 2025 8 min Case Studies Download Full Case Study Copy Link In collaboration with patient advocates and scientific advisors, Vitaccess has supported a...
Cystic Fibrosis Case Study
Flexible patient-centric study demonstrating real-world impact of therapy in late-stage developmentJun 25, 2025 8 min Case Studies Download Full Case Study Copy Link Vitaccess has assisted a US-based biopharmaceutical company in generating evidence on CF treatment...
Melanoma Case Study
Innovative Vitaccess Real™ platform has been harnessed in a long-term real-world observational study in melanoma, developed in collaboration with a UK-based charity and melanoma patients.
Charcot-Marie-Tooth Disease
Innovative patient-centric digital observational study in rare disease. Innovative research organization, Vitaccess, has leveraged its flexible platform to connect a European biopharmaceutical company in real time to Charcot-Marie-Tooth disease (CMT) patients worldwide.
Myasthenia Gravis
Vitaccess has collaborated with clinicians and patient representatives to connect a European biotechnology company with a global cohort of myasthenia gravis (MG) patients. Our client is using the data in pharmacoeconomic models and reimbursement submissions.
Innovative caregiver burden study for HTA
Vitaccess is partnering with a pharmaceutical company on an international, patient-centric real-world evidence (RWE) study. This observational longitudinal study is designed to identify and increase understanding of the impact of living with a rare autoimmune, neuromuscular disease.
The client is seeking recommendation from health technology assessment (HTA) bodies across Europe for a new product to treat this disease. Some HTA bodies will include impact on caregiver burden within the value assessment of new health technologies, however, there is a gap in research on the health-related quality of life of the caregivers of patients living with the disease.
